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Atrial ﬁbrillation (AF) is the most common, sustained clinical tachyarrhythmia associated
with signiﬁcant morbidity and mortality. AF is a persistent condition with progressive struc-
tural remodeling of the atrial cardiomyocytes due to the AF itself, resulting in cellular
changes commonly observed in aging and in other heart diseases. While rhythm control
by electrocardioversion or drug treatment is the treatment of choice in symptomatic AF
patients, its efﬁcacy is still limited. Current research is directed at preventing ﬁrst-onset
AF by limiting the development of substrates underlying AF progression and resembles
mechanism-based therapy. Upstream therapy refers to the use of non-ion channel anti-
arrhythmic drugs that modify the atrial substrate- or target-speciﬁc mechanisms of AF,
with the ultimate aim to prevent the occurrence (primary prevention) or recurrence of the
arrhythmia following (spontaneous) conversion (secondary prevention). Heat shock pro-
teins (HSPs) are molecular chaperones and comprise a large family of proteins involved
in the protection against various forms of cellular stress. Their classical function is the
conservation of proteostasis via prevention of toxic protein aggregation by binding to (par-
tially) unfolded proteins. Our recent data reveal that HSPs prevent electrical, contractile,
and structural remodeling of cardiomyocytes, thus attenuating the AF substrate in cellu-
lar, Drosophila melanogaster, and animal experimental models. Furthermore, studies in
humans suggest a protective role for HSPs against the progression from paroxysmal AF to
persistent AF and in recurrence of AF. In this review, we discuss upregulation of the heat
shock response system as a novel target for upstream therapy to prevent derailment of
proteostasis and consequently progression and recurrence of AF.
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MANAGEMENT OF ATRIAL FIBRILLATION BY UPSTREAM
THERAPY
Atrial ﬁbrillation (AF) is the most common clinical tachyarrhyth-
mia which signiﬁcantly contributes to cardiovascular morbidity
and mortality, mainly through stroke and heart failure (Nattel,
2002). The incidence of AF is escalating due to the increased
prevalence of risk factors constituting a substrate for AF, such
as obesity (Wang et al., 2004), metabolic syndrome (Watanabe
et al., 2008) and increasing age (Feinberg et al., 1995). In addi-
tion to the increased ﬁrst-onset of AF, also the progression of
the arrhythmia poses problems, as the longer AF persists the less
effective pharmacological and electrical cardioversion therapies
are (Van Gelder et al., 1996). In patients with symptomatic AF,
rhythm control is the treatment of choice (Camm et al., 2010).
However, the effective reversal to sinus rhythm is still inade-
quate. Therefore, recent research focuses on the identiﬁcation of
mechanisms underlying AF substrate induction and maintenance,
which have led to several novel upstream therapeutic approaches,
including angiotensin-converting enzyme inhibitors, aldosterone
antagonists, statins, polyunsaturated fatty acids, and colchicine
(Imazio et al., 2011; Savelieva et al., 2011b). Upstream therapy
refers to the use of non-ion channel anti-arrhythmic drugs that
modify the atrial substrate- or target-speciﬁc mechanisms of AF
with the ultimate aim to prevent the occurrence (primary pre-
vention) or recurrence (secondary prevention) of the arrhythmia
(Van Gelder et al., 2010; Savelieva et al., 2011a).
It has been recognized that electrical and structural remodeling
of cardiomyocytes create a substrate for AF (Nattel et al., 2008).
Nevertheless, the exact molecular mechanisms that underlie car-
diomyocyte remodeling andAFprogression are as yet unidentiﬁed.
We recently obtained evidence that derailment of proteostasis (i.e.,
the homeostasis of protein production, breakdown, and function)
constitutes an important substrate for induction and progression
of AF (Brundel et al., 2001, 2002, 2006b). Proteostasis involves
controlling the concentration, conformation, binding interaction,
kinetics, and location of individual proteins.Derailment of cellular
proteostasis results in many systemic diseases including cardio-
vascular disorders (Balch et al., 2008). Cells respond to a loss of
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FIGURE 1 | Overview of AF-promoting factors contributing to first-onset
AF. Various clinical conditions induce AF-promoting factors. These factors can
induce triggers for AF or are responsible for the loss of proteostatic control,
thereby inducing remodeling, and creating a substrate for AF. Triggers will act
on the vulnerable substrate to induce ﬁrst-onset AF. Prevention and/or
normalization of the cardiomyocyte proteostasis by inducing HSP expression
could prevent AF substrate formation and prove an effective approach in
preventing ﬁrst-onset AF in response to various AF-promoting factors.
proteostatic control by inducing the heat shock response (HSR)
resulting in the expression of heat shock proteins (HSPs) that facil-
itate protein folding and function (Westerheide and Morimoto,
2005). Consequently, an emerging target candidate for upstream
therapy of AF is the upregulation of HSPs. Indeed, HSP induction
alleviates the occurrence and recurrence of AF in various experi-
mentalmodel systems forAF (Brundel et al., 2006a,b, 2008; Sakabe
et al., 2008). Furthermore, studies in humans suggest a protective
role for HSPs against progression from paroxysmal AF to persis-
tent AF (Brundel et al., 2006a) and the restoration of sinus rhythm
in patients with persistent AF (secondary prevention; Cao et al.,
2011).
Here we discuss the concept that derailment of cardiomyocyte
proteostasis constitutes an important aspect of the substrate for
AF. In addition we examine the evidence for induction of the HSR
system as a novel target for upstream therapy to prevent the occur-
rence and the recurrence of AF and address its possible modes of
action.
MECHANISMS UNDERLYING AF INITIATION AND
PROGRESSION: DERAILMENT OF PROTEOSTASIS
Although the exact molecular mechanism(s) underlying AF ini-
tiation, maintenance, and progression has not yet been com-
pletely elucidated, an important recognitionwas thatAF induction
required a suitable substrate as well as a trigger that acts on the
substrate (Nattel et al., 2008). Various clinical conditions, e.g.,
several heart diseases, hypertension and cardiac surgery, are risk
factors for the ﬁrst-onset of AF, as they create a substrate(s) and/or
trigger(s) for the initiation of AF (Figure 1; Benjamin et al., 1998;
Kannel et al., 1998; Chelazzi et al., 2011). Key AF-promoting fac-
tors have been identiﬁed, including inﬂammation, oxidative stress,
active Rho-GTPase, ﬁbrosis, and atrial muscle bundle dissociation
(Allessie et al., 2010; de Groot et al., 2010), which induce loss of
proteostatic control, creating a substrate for AF. Subsequent trig-
gers will act on the substrate and will induce AF (Sah et al., 1999;
Dudley et al., 2005; Engelmann and Svendsen, 2005; Adam et al.,
2007; Burstein and Nattel, 2008; Nattel et al., 2008).
Once AF is initiated, AF itself will induce further electrical
and structural remodeling in a manner that contributes to AF
maintenance and progression (Wijffels et al., 1995). A conceptual
model is depicted in Figure 2. Electrical remodeling resulting in
shortening of actionpotential duration (APD), slowing of conduc-
tion, and abnormal calcium handling will favor AF maintenance
(Dobrev andVoigt, 2011). When AF persists, the calcium overload
causes irreversible changes in structural remodeling, especially
cardiomyocyte hibernation (Ausma et al., 1997b, 2000b; Brundel
et al., 2002). Hibernation is characterized by irreversible degra-
dation of the myoﬁbril structure (myolysis) and mitochondrial
damage, implying impaired energy production and release of reac-
tive oxygen species (ROS), which leads to contractile dysfunction
(Vanoverschelde et al., 1993; Ausma et al., 1997a; Sherman et al.,
2000; Bito et al., 2004). Other characteristics are redistribution
of nuclear chromatin and pathological gene expression reveal-
ing a deﬁciency in healthy cardiomyocyte proteostasis (Ausma
et al., 1995, 1997a,b, 1998; Allessie et al., 2002; Thijssen et al.,
2004). While early electrical remodeling is reversible (Schotten
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FIGURE 2 | Overview of AF-induced derailment of cardiomyocyte
proteostasis. AF induces time-related progressive myocyte remodeling. First,
AF causes cellular Ca2+ overload and oxidative stress, which results in a direct
inhibition of the L-type Ca2+ channel, shortening of action potential duration,
and contractile dysfunction. These changes have an early onset and are
reversible. The early processes protect the cardiomyocyte against Ca2+
overload but at the expense of creating a substrate for persistent AF.When
AF persists, derailment of proteostasis occurs via activation of calpain,
kinases/phosphatases, RhoA-GTPase, HDACs, and exhaustion of protective
HSPs. The key modulators also activate each other. Derailment of
proteostasis results in irreversible myolysis/hibernation, alterations in
structural proteins and pathological gene expression, which are substrates for
impaired contractile function and AF persistence. Upstream therapies are
directed at modifying the substrate for AF progression. Normalization of the
cardiomyocyte proteostasis by inducing HSP expression might represent an
effective approach to manage clinical AF.
et al., 2003), the derailment of proteostasis underlies irreversible
structural remodeling and thereby AF progression (Allessie et al.,
2002; Brundel et al., 2002;Ausma et al., 2003; Cha et al., 2004; Todd
et al., 2004). We and others identiﬁed various molecular mecha-
nisms that underlie derailment of proteostasis and AF progression
and recurrence (Brundel et al., 2001, 2002, 2006b; Ke et al., 2008,
2011; Zhang et al., 2011a).
ION CHANNEL CURRENTS AND CALCIUM HANDLING
DuringAF, atrial cardiomyocytes are subjected to very rapid (400–
600 times per minute) and irregular ﬁring, causing a rapid Ca2+
overload resulting in functional downregulation of the L-type
Ca2+ channel, which leads to shortening of the APD and con-
tractile dysfunction (hypocontractility), thus providing a further
substrate for AF (Figure 2; Goette et al., 1996; Leistad et al., 1996;
Ausma et al., 2000a; Brundel et al., 2001; Qi et al., 2008). Decreased
ICaL has been consistently found in atrial remodeling, which is
believed to signiﬁcantly contribute to electrical remodeling and
AF progression (Van Wagoner et al., 1997; Yue et al., 1997). The
functional changes have a rapid onset following initiation of AF
and are reversible (Schotten et al., 2003). In addition to the L-
type Ca2+ channel, also other channel currents are affected, as
reviewed in Dobrev and Voigt (2011). Ion channel currents are
regulated by expression level, phosphorylation, and redox status
of the channel, all of which are altered during AF (Brundel et al.,
1999; Wang, 2003; Dobrev and Voigt, 2011). In dog atrial car-
diomyocytes, tachypacing induced the activation of calcineurin
via the Ca2+/calmodulin system,which in turn changes cardiomy-
ocyte proteostasis by stimulating nuclear translocation of NFAT,
resulting in transcriptional and translational downregulation of
the L-type calcium channel resulting in atrial remodeling and AF
progression (Qi et al., 2008). Phosphorylation status of ion chan-
nels are altered due to changes in activity of various kinases and
phosphatases, such as enhanced CaMKII, PP1, and PP2a activ-
ity (Anderson, 2004; Dobrev and Voigt, 2011). Further, oxidative
stress during AF can contribute to changes in redox status, thereby
altering ion channel currents (Wang, 2003; Dobrev and Voigt,
2011).
KINOMICS ACTIVITY AND TARGET PROTEINS
Various kinases and phosphatases become activated during AF
and contribute to AF-induced remodeling and contractile dys-
function (Anderson, 2004; Christ et al., 2004; El-Armouche et al.,
2006; Greiser et al., 2007; Dobrev and Nattel, 2008; Ke et al.,
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2011). In addition tomodiﬁcation of ion channel currents through
(de)phosphorylation, also the function of other downstream tar-
get proteins are affected by the altered activity of kinases and
phosphatases, including calcium handling proteins, such as RyR2
and PLB (Schwinger et al., 1999; Hagemann and Xiao, 2002;
Bers, 2006; Carter et al., 2011). Modiﬁcation of calcium han-
dling protein function will contribute to calcium overload and
subsequent contractile dysfunction (Dobrev and Nattel, 2008).
Furthermore, also kinases involved in post-translational modiﬁ-
cations of structural proteins, such as actin, have been implicated
in AF-induced remodeling. Tachypacing-induced activation of
RhoA-GTPase and downstream Rho-kinase (ROCK), induces F-
actin stress ﬁber formation (Figure 2;Ke et al., 2011). Preventionof
stress ﬁber formation by ROCK-inhibition or HSP expression pre-
vented tachypacing-induced remodeling (Ke et al., 2011). These
ﬁndings imply a key role for alterations in kinomics in derailed
proteostasis and progression of AF.
HDAC AND PROTEASE ACTIVITY
Histone deacetylases (HDACs) have been recently implicated inAF
(Backs et al., 2006; Liu et al., 2008; Zhang et al., 2011b). CaMKII
was found tophosphorylate class IIa histonedeacetylase (HDAC4),
resulting in the expression of pathological cardiac genes, contrac-
tile dysfunction, and structural remodeling, such as hibernation,
all substrates forAF (Backs et al., 2006).HDAC inhibition has been
shown to reverse atrial arrhythmia inducibility and ﬁbrosis in car-
diac hypertrophy (Liu et al., 2008). Recently we showed that selec-
tive inhibition of HDAC6 protected against tachypacing-induced
contractile dysfunction and structural remodeling in HL-1 atrial
cardiomyocytes and Drosophila (Zhang et al., 2011b), indicating
the involvement of HDACs in tachypacing-induced cardiomyocyte
remodeling. In addition to HDACs, also the cysteine protease cal-
pain is activated during AF. Calpain is persistently activated by the
AF-induced intracellular Ca2+ overload, which results in degra-
dation of contractile and structural proteins (Brundel et al., 2002;
Ke et al., 2008), leading to myolysis, thereby further contributing
to irreversible structural remodeling and AF progression.
Thus, AF-induced derailment of proteostasis includes changes
in ion channel function, kinomics, HDAC and calpain activa-
tion and underlies reversible electrical remodeling and irreversible
structural remodeling and thereby AF initiation and progression.
HEAT SHOCK PROTEINS PROTECT AGAINST AF INITIATION
AND PROGRESSION
It has been recognized that heat shock transcription factor 1
(HSF1) is an important regulator of proteostasis by controlling the
expression of major HSPs, including HSPB1 (HSP27), HSPA1A
(HSP70), and HSPC1 (HSP90), that facilitate protein folding,
localization, and function (Balch et al., 2008; Powers et al., 2009).
Induction of HSPs provides cytoprotective effects against stress-
induced derailment of proteostasis and is beneﬁcial in various
cardiac diseases (Table 1; Marber et al., 1995; Plumier et al., 1995;
Efthymiou et al., 2004; Kupatt et al., 2004; Brundel et al., 2006b;
Hayashi et al., 2006; Inagaki et al., 2006; Kim et al., 2006; Kwon
et al., 2007; Lin et al., 2007; Rajasekaran et al., 2007; Ago et al.,
2008; Balch et al., 2008; Powers et al., 2009; Fan and Kranias, 2011;
Ke et al., 2011). Therefore, recent studies have investigated the car-
dioprotective potential of HSPs in AF, focusing on AF induction
as well as progression.
HSPs IN THE PREVENTION OF FIRST-ONSET AF (PRIMARY PREVENTION)
Heat shock proteins protect against a variety of AF-promoting fac-
tors contributing to ﬁrst-onset AF (Figure 1). Protective effects of
HSPs against cell death, ﬁbrosis, Rho-GTPase activation, oxida-
tive stress, and inﬂammation have been described, indicating their
potential in preventing loss of proteostatic control and formation
of AF substrates (Arya et al., 2007; Wakisaka et al., 2007; Jones
et al., 2011; Ke et al., 2011). It is unclear if HSPs could affect the
formation of triggers. However, since triggers need a vulnerable
Table 1 | Major cardioprotective heat shock proteins, localization, expression, and cardiac disease protective effects.
Family name Protective member
(alternative name)
Cardiac disease Localization Cardiac
expression
Reference
HSPA HSPA1A (HSP70) Ischemic heart
disease, hypertrophy
Cytosol +++ Marber et al. (1995), Plumier et al. (1995),
Kim et al. (2006)
DNAJ DNAJA3 (HSC40) Dilated
cardiomyopathy
Cytosol/nuclear +++ Hayashi et al. (2006)
DNAJB5 (HSP40) Hypertrophy Cytosol/nuclear +++ Ago et al. (2008)
HSPB HSPB1 (HSP25,
HSP27, HSP28)
AF, ischemic heart
disease
Cytosol +++ Efthymiou et al. (2004), Brundel et al. (2006b),
Kwon et al. (2007), Ke et al. (2011)
HSPB5 (αβCrystallin,
CRYAB, CRYA1)
(dilated)
cardiomyopathy
Cytosol ++++ Inagaki et al. (2006), Rajasekaran et al. (2007)
HSPB6 (HSP20, p20) AF, ischemic heart
disease
Cytosol ++ Ke et al. (2011), Fan and Kranias (2011)
HSPB7 (cvHSP) AF Cytosol +++++ Ke et al. (2011)
HSPB8 (HSP22, H11) AF Cytosol ++ Ke et al. (2011)
HSPD HSPD1 (HSP60) Heart failure Mitochondria ++++ Lin et al. (2007)
HSPC HSPCA (HSP90) Ischemic heart
disease
Cytosol ++++ Kupatt et al. (2004)
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substrate to act on (Allessie et al., 2010), the prevention of AF sub-
strate formation might be sufﬁcient to protect against ﬁrst-onset
AF. Indeed in various models for ﬁrst-onset AF,HSPs provide pro-
tection against AF substrate formation and hence AF initiation.
In a canine model (acute) atrial ischemia related AF, geranylger-
anylacetone (GGA) pre-treatment induced HSPA1A expression
and revealed protection against prolongation of effective refrac-
tory period (ERP) and atrial conduction abnormalities (Brundel
et al., 2006b; Sakabe et al., 2008), thereby preventing AF initia-
tion. These observations suggest that HSP induction may protect
against some forms of AF in patients with coronary artery dis-
ease. Furthermore, a recent study in rats showed that induction of
HSPA1A prevents both the angiotensin II mediated atrial ﬁbrosis
and increased atrial vulnerability forAF induction (Wakisaka et al.,
2007). The ﬁndings suggestHSPA1A to play a role in inhibiting the
development of a non-cardiomyocyte substrate for AF induction.
In two clinical studies, HSPA1A has been implicated as cardiopro-
tective, showing a correlation between HSPA1A atrial expression
levels and reduced incidence of post-operative AF in patients in
sinus rhythm undergoing cardiac surgery (St Rammos et al., 2002;
Mandal et al., 2005).
In addition to HSPA1A, other HSPs might be involved in pri-
mary prevention of AF. In patients with AF, increased mitochon-
drial HSP expression levels, i.e.,HSPD1 [37],HSPE1 and mortalin
(HSPA9B; Kirmanoglou et al., 2004) have been reported. In addi-
tion, increased HSPD1 antibody levels in the serum of patients
have been associated with the occurrence of post-operativeAF (Oc
et al., 2007), suggesting HSPD1 as a marker for mitochondrial and
cardiac damage and subsequent increased risk for AF. Increased
expression of mitochondrial chaperones could contribute to an
increased protection against oxidative stress. Therefore, these HSP
family members might contribute to survival of cardiomyocytes
by maintaining mitochondrial integrity and capacity for ATP
generation. To date, however, several studies showed opposing
correlations between the expression of mitochondrial HSPs and
AF (Kirmanoglou et al., 2004; Oc et al., 2007; Yang et al., 2007),
thereby obscuring their involvement in protection against AF.
HSPs IN THE PREVENTION OF AF PROGRESSION AND RECURRENCE
(SECONDARY PREVENTION)
Various in vitro and in vivo models for tachypacing-induced AF
progression identiﬁed HSPs to protect against the derailment of
proteostasis and cardiomyocyte remodeling. In tachypaced HL-
1 atrial cardiomyocytes and Drosophila melanogaster models for
AF, a general HSP induction via a mild heat shock or by a HSP-
inducing drug GGA, conserved cardiomyocyte proteostasis during
tachypacing and protected against subsequent electrical, contrac-
tile, and structural remodeling (Brundel et al., 2006a,b; Zhang
et al., 2011a). Furthermore, in canine models for AF progression,
GGA pre-treatment induced HSP (HSPA1A and HSPB1) expres-
sion and revealed protective effects against shortening of ERP,
shortening of APD, reductions in L-type Ca2+ current, and AF
progression (Brundel et al., 2006b; Sakabe et al., 2008). Also, in
clinical studies, a potent HSR and high HSPB1 levels have been
associated with restoration of normal sinus rhythm in patients
with permanent AF after mitral valve surgery (Cao et al., 2011).
Two other studies comparing paroxysmal vs. persistent AF and
sinus rhythm, found an inverse correlation between HSPB1 atrial
expression andAF duration and extend of myolysis (Brundel et al.,
2006a; Yang et al., 2007). Suggesting, a temporary activation of the
HSR during a short duration of AF but exhaustion in time, related
to the duration of AF. Consequently, cardiomyocytes lose the abil-
ity for proteostatic control, inducing remodeling, which will result
in AF progression and recurrence.
Further studies investigated the role of individual HSPs in pro-
tection against tachypacing-induced remodeling. HSPB1, and not
HSPA1A, was found to play an important role, as its exclusive
overexpression appears sufﬁcient to protect against tachypacing-
induced remodeling, comparable to GGA pre-treatment (Brundel
et al., 2006b). Conversely, the protective effect of a general HSR or
GGA pre-treatment on tachypacing-induced changes was annihi-
lated by a selective knockdown of HSPB1. However, in addition
to HSPB1, also other HSPB family members (HSPB6, HSPB7,
and HSPB8) protect against AF-induced structural remodeling
independently from HSPB1 (Ke et al., 2011). Hence, sole overex-
pression of multiple HSPB family members prevent against AF-
induced cardiomyocyte remodeling and AF progression by pre-
serving cell proteostasis, thereby demonstrating their therapeutic
potential in AF.
Taken together, there seems to be a strong case for induction
of HSPs to prevent AF initiation, recurrences, and progression,
by attenuation of electrical, contractile, and structural cardiomy-
ocyte remodeling. There are strong indications that this effect is
via normalization of cell proteostasis.
MODE OF ACTION FOR HSPs TO NORMALIZE PROTEOSTASIS
It has been recognized that HSPs protect against derailment of
proteostasis by preventing cardiomyocyte remodeling at different
stages (Figures 1 and 2). The exact mechanisms in prevention of
AF initiation (primary prevention) and recurrences (secondary
prevention) are not known, but are likely due to HSP regulated
protection against various AF-promoting factors that induce the
substrate for AF initiation and progression.
ION CHANNEL CURRENTS
An ion channel current is dependent on the expression level, phos-
phorylation and redox status of the channel (Hara et al., 2002;
Wang, 2003; Dobrev andVoigt, 2011), as well as the stability of the
cytoskeleton (Sadoshima et al., 1992) and Rho-GTPase activity
(Pochynyuk et al., 2007). The HSP-inducing drug GGA previously
showed protective effects against tachypacing-induced reductions
in L-type Ca2+ current and shortening of APD (Brundel et al.,
2006b). Furthermore, several studies have shown protective effect
of HSPs on almost all of these regulating factors. HSPs are known
to interact and, in some cases, inhibit kinases and phosphatases,
who’s activity is altered during AF (Ding et al., 1998; Laksh-
mikuttyamma et al., 2004; Dobrev, 2006; Peng et al., 2010; Fan
and Kranias, 2011; Qian et al., 2011), thereby potentially prevent-
ing or normalizing the phosphorylation status of ion channels,
especially L-type Ca2+ channel (Christ et al., 2004). Furthermore,
severalHSPs (includingHSPB1)were shown to provide protection
against oxidative stress, thereby potentially preventing or restor-
ing the redox status of the ion channels (Kalmar and Greensmith,
2009). If HSPs can inﬂuence the expression levels of ion channels is
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currently not known. Lastly, also the stability of the actin cytoskele-
ton andRho-GTPase activity are regulated by the smallHSP family
members (see below; Sugiyama et al., 2000; Mounier and Arrigo,
2002; Golenhofen et al., 2004; Brundel et al., 2006b; Salinthone
et al., 2008; Ke et al., 2011; Zhang et al., 2011a). The ﬁndings reveal
a protective role of HSP againstAF-induced changes in ion channel
current, including reductions in the L-type Ca2+ current.
KINOMICS ACTIVITY AND TARGET PROTEINS
Various kinases and phosphatases reveal changed activity during
AF, which contributes to cardiomyocyte remodeling depending
on their target proteins (Anderson, 2004; Christ et al., 2004; El-
Armouche et al., 2006; Greiser et al., 2007; Dobrev and Nattel,
2008; Ke et al., 2011). In addition to ion channels, known tar-
gets are transcription factors, various calcium handling proteins
and the actin cytoskeleton. Changes in transcription factor phos-
phorylation, regulates gene expression and hence can induce an
altered gene expression proﬁle, possibly contributing to cardiomy-
ocyte hibernation. Interestingly,HSPB1was shown to interactwith
certain (downstream) kinases, such as IkappaB kinase and c-Jun
N-terminal kinase (JNK), thereby suppressing activation of the
transcription factor NF-kappaB (Park et al., 2003; Kammanadim-
inti and Chadee, 2006). Interestingly, these kinases have also been
found to be modulated during AF (Li et al., 2001; Cardin et al.,
2003). In addition, HSPB1 is known to interact with other kinases
and phosphatases and thereby might prevent the activation of
other downstream transcription factors (Ding et al., 1998; Laksh-
mikuttyamma et al., 2004; Dobrev, 2006; Peng et al., 2010; Fan and
Kranias, 2011; Qian et al., 2011).
Changes in phosphorylation status of calcium handling pro-
teins will affect the calcium homeostasis in cardiomyocytes. It
is generally accepted that AF-induced abnormalities in intra-
cellular Ca2+ handling leads to atrial cardiomyocyte stress and
induces remodeling that contributes to the progression of AF
(Qi et al., 2008; Chelu et al., 2009). A calcium overload can
be caused by an increase in L-type Ca2+ channel activity, or
a changed activity of calcium handling proteins such as RyR2,
SR Ca2+ ATPases, or Na+/Ca2+ exchanger. These rapid changes
in activity of proteins involved in calcium handling are modu-
lated by kinases and/or phosphatases, including CaMKII and PP1,
of which the activities are increased during AF (Christ et al.,
2004; Vest et al., 2005). Interestingly, studies showed that HSPs
interact with CaMKII (Peng et al., 2010), calcineurin (Laksh-
mikuttyamma et al., 2004), and PP1 (Dobrev, 2006; Fan and
Kranias, 2011). Furthermore, HSPB6 was shown to inhibit PP1
activity (Qian et al., 2011). Also, HSPs increase SR Ca2+ ATPase
activity and stimulate both the reuptake of Ca2+ into the SR and
the extrusion of Ca2+ out of the cardiomyocyte via Na+/Ca2+
exchanger (Liu et al., 2006; Chen et al., 2010). These ﬁndings sug-
gest that HSPs can protect against (tachypacing-induced) changes
in calcium handling proteins, resulting in attenuation of AF
progression.
Atrial ﬁbrillation is known to activateRhoA-GTPase andROCK
and induces subsequent F-actin stress ﬁber formation contribut-
ing to contractile dysfunction (Ke et al., 2011). Several HSPB
family members (HSPB1, HSPB6, and HSPB7) were recently
shown to bind to actin and prevent F-actin stress ﬁber formation
downstream of RhoA/ROCK. HSPB1 and HSPB6 even promoted
actin stress ﬁber disassembly. HSPB8 did not directly bind actin,
but instead inhibited upstream RhoA-GTPase activation, thereby
preventing F-actin stress ﬁber formation (Ke et al., 2011). As most
HSPB family members are known to protect the actin cytoskele-
ton from remodeling, this action likely represents an important
mechanism by which HSPBs attenuate AF-induced derailment of
proteostasis and cardiomyocyte remodeling.
HDAC AND PROTEASE ACTIVITY
Recently, HDAC6 has been implicated in AF-induced cardiomy-
ocyte remodeling (Zhang et al., 2011b). In contrast to the mod-
ulation effect of HSPs on kinases and phosphatases, no direct
interactions between HSPs and HDACs have yet been described.
However, since various kinases and phosphatases regulate the
activity of HDACs (de Ruijter et al., 2003) HSPs could theo-
retically modulate HDAC activity by indirect inhibition of the
kinase/phosphatase activity.
In contrast to HDAC activity, HSPs have been shown to atten-
uate activation of the cysteine protease calpain and subsequently
structural remodeling. In a Drosophila model for AF, DmHSP23,
presumably the ortholog for human HSPB1, prevents induction of
calpain activity, mitochondrial damage, and myolysis (Figure 3).
Other studies have also described the modulating effects of HSPB1
on cysteine proteases such as caspase 3 (Garrido et al., 1999; Con-
cannon et al., 2001). Our observation that HSPB protects against
AF-induced mitochondrial damage, indicates that it attenuates the
impairment of energy production and release of ROS (Figure 3).
This ﬁnding suggests a protective effect of HSP against induction
of early oxidative stress (see below; Figure 2).
HSPs AND OXIDATIVE STRESS
Interestingly, inAF patients, an increase in oxidative stress markers
has been observed and anti-inﬂammatory or anti-oxidant treat-
ment with glucocorticoids and statins (Shiroshita-Takeshita et al.,
2004, 2006, 2007; Sanchez-Quinones et al., 2008) suppressed atrial
remodeling and have shown some clinical value in prevention of
post-surgery AF (primary prevention; Camm et al., 2010) sub-
stantiating a role for oxidative stress in AF-induced remodeling.
Glucocorticoids and statins have been reported to induce several
HSPs (HSPB1, HSPB5, and HSPA1A; Nègre-Aminou et al., 2002;
Son et al., 2005), leaving open the possibility that part of their pro-
tective pleiotropic effects is due to overexpression of HSPs. HSP
induction can provide protection against oxidative stress by sev-
eral mechanisms. HSPB1 is known to regulate the redox status of
cardiomyocytes by maintaining glutathione in its reduced form,
thus decreasing the amount of ROS produced in cells exposed
to oxidative stress or tumor necrosis factor TNFalpha (Arrigo,
2007). HSPB1 may therefore prevent tachypacing-induced alter-
ations in redox status of cardiomyocytes and thereby preserve
cell proteostasis and electrophysiological and contractile function
of the cardiomyocyte in AF. In addition to alterations in redox
state, oxidative stress can also contribute to actin cytoskeleton
instability, resulting in impairment of cardiomyocyte contractile
function. Several members of the HSPB family were found to bind
the actin ﬁlaments and prevent their disruption in response to
various stresses, including AF (Sugiyama et al., 2000; Mounier
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FIGURE 3 | HSP23 overexpressing Drosophila are protected against
tachypacing-induced structural remodeling, including loss of
sarcomeres (myolysis) and mitochondrial damage. (A) Left panel shows
light microscopic structure of the heart wall in normal paced and
tachypaced control and DmHSP23 overexpressing strains. Right panel
shows electron microscopic details of the cardiomyocytes and
mitochondria. Arrowhead shows loss of sarcomeres in the heart wall and
asterisk marks mitochondrial damage. (B)Tachypacing induces calpain
activity, and DmHSP23 (UAS-actin GAL4-DmHSP23) overexpressing strains
were protected. *P <0.05 vs. control normal paced, #P <0.05 vs. control
tachypaced. Figure adapted from Zhang et al. (2011a).
and Arrigo, 2002; Golenhofen et al., 2004; Brundel et al., 2006b;
Salinthone et al., 2008; Zhang et al., 2011a). In addition, HSPB
family members were also shown protective against AF-induced
mitochondrial damage (Zhang et al., 2011a), thereby limiting the
release of ROS.
THERAPEUTIC POTENTIAL OF HSP-INDUCING DRUGS IN AF
Pharmacological and other approaches (e.g., viral gene trans-
fer), preventing the substrate for AF are being studied, with the
hope that they might be useful therapeutic agents in treating AF
(Amit et al., 2010; Dobrev and Nattel, 2010; Igarashi et al., 2012).
Focusing on the current pharmacological options, the efﬁcacy of
commonly used drugs, including glucocorticoids and statins, on
remodeling is limited (Dobrev and Nattel, 2010) and (serious)
adverse effects have been reported, indicating the need for more
effective therapeutic agents with less adverse effects. Since derail-
ment of cellular proteostasis results in cardiomyocyte remodeling
and AF progression and derailment is counteracted by HSPs,
pharmacological induction of the HSR seems to represent a key
target for upstream therapy.
Currently, GGA represents the most promising compound for
the pharmacological induction of HSPs. Until now it is the most
efﬁcaciousHSPboosting drug (Brundel et al., 2008). Furthermore,
in contrast to other HSP inducers, GGA is a non-toxic compound
shown to be capable of inducingHSP expression in various tissues,
including gastric mucosa, intestine, liver,myocardium, retina, kid-
ney, and central nervous system. In addition GGA is used clinically
in Japan since 1984 as an antiulcer drug (Murakami et al., 1981)
and no serious adverse reactions have been reported (Unoshima
et al., 2003; Katsuno et al., 2005;Yanaka et al., 2007; Fujimura et al.,
2012). GGA rapidly induces HSP expression (HSPB,HSPA1A, and
HSPC family members) via activation of the HSF1, in response
to a variety of stresses, whereas its effect is weaker under non-
stress conditions,providing itsmain effectwhen andwhere needed
(Hirakawa et al., 1996; Yamanaka et al., 2003).
The protective effect of GGA-induced HSP expression on early
and late remodeling, suggests that it has value in the prevention
of clinical AF, although this still needs to be assessed in clinical
trials (Brundel et al., 2006a,b; Sakabe et al., 2008). So far, the pro-
tective action of GGA has been established regarding electrical,
contractile, and structural remodeling in in vitro HL-1 and dog
atrial cardiomyocytes and in in vivo Drosophila and dog models
for AF. GGA also has beneﬁcial effects in AF of different origin,
as observed in AF induced by congestive heart failure and acute
ischemia (Shiroshita-Takeshita et al., 2007; Sakabe et al., 2008).
The broad protective effects of GGA against AF-related derail-
ment of proteostasis and atrial remodeling suggest that inducers
of theHSRhave substantial therapeutic value for clinicalAF.Other
drugs that induce HSP expression, such as bimoclomol, atorvas-
tatin, cyclosporine A, and dexamethasone, still need to be tested
for their protective effects against AF-induced remodeling. Never-
theless, their therapeutic potential in other cardiac diseases, such
as ischemic heart disease, have already been documented (Sun
et al., 2000; Ooie et al., 2001; Chen et al., 2002; Lubbers et al., 2002;
Efthymiou et al., 2005; Shinohara et al., 2007).
In summary, AF results in a derailment of cardiomyocyte pro-
teostasis by inducing reversible electrical and irreversible struc-
tural remodeling. There is strong evidence that induction of HSPs,
in particular HSPB family members, normalizes proteostasis and
thereby prevents electrical and structural remodeling. Known
upstream targets for HSP protection include L-type Ca2+ chan-
nel, calciumhandling proteins, calpain,RhoA-GTPase, andF-actin
stress ﬁbers. Ultimately, the induction of HSPs, by proteostasis reg-
ulators such as GGA, may prevent the occurrence of AF (primary
prevention) and may contribute to enhance therapeutic efﬁcacy
and treatment options for patient with AF in delaying progression
towardpersistentAF and/or improve the outcomeof cardioversion
(secondary prevention).
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